March 2, 2007 – At an HIV Conference, several companies reported good results from new approaches to HIV/AIDS treatments: Pfizer said maraviroc produced an undetectable level of virus in twice as many patients as an optimized regimen of drugs; Merck and Gilead reported that their oral integrase inhibitors significantly reduced viral load; Roche and Trimeris revealed Fuzeon produced an undetectable level of HIV in 98% of the recipients; and Idenix Pharma reported positive pre-clinical data of two novel non-nucleoside reverse transcriptase inhibitors. Pharmion announced European regulators accepted its filing for approval of Thalidomide; Novavax licensed IP for a new virus-like particle technology, and Idenix won approval in China for Sebivo (telbivudine) for hepatitis B. The Centient Biotech 200™ fell 44 points to 3822, a loss of 1.13%. For the week, biotech is down 232 points or almost 6%. More details...
